BiotechTube

sparsentan + irbesartan + Dapagliflozin

Phase 3Active
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Immunoglobulin A Nephropathy

Conditions

Immunoglobulin A Nephropathy

Trial Timeline

Dec 11, 2018 → Jul 1, 2026

NCT ID
NCT03762850

About sparsentan + irbesartan + Dapagliflozin

sparsentan + irbesartan + Dapagliflozin is a phase 3 stage product being developed by Travere Therapeutics for Immunoglobulin A Nephropathy. The current trial status is active. This product is registered under clinical trial identifier NCT03762850. Target conditions include Immunoglobulin A Nephropathy.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03762850Phase 3Active

Competing Products

11 competing products in Immunoglobulin A Nephropathy

See all competitors
ProductCompanyStageHype Score
ABBV-383 (Etentamig)AbbViePhase 1/2
41
zigakibartNovartisPhase 2
52
iptacopanNovartisPhase 3
77
CCX168AmgenPhase 2
51
InebilizumabAmgenPhase 2
51
Rilzabrutinib + Placebo + GlucocorticoidSanofiPhase 3
76
rilzabrutinib + GlucocorticoidsSanofiPhase 2
51
FelzartamabBiogenPhase 2
49
Felzartamab + PlaceboBiogenPhase 3
74
SparsentanTravere TherapeuticsPhase 2
47
SparsentanTravere TherapeuticsPhase 2
47

Other Products from Travere Therapeutics

SparsentanApproved
80
PegtibatinasePhase 3
72
sparsentan + IrbesartanPhase 3
72
Fosmetpantotenate + PlaceboPhase 3
72
PegtibatinasePhase 3
72